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Nonalcoholicfattyliverdisease(NAFLD)isthemostfrequentchronicliverdiseaseandshowsvariousinﬂammatorychangesinthe
liver. Among those inﬂammatory cells, natural killer T (NKT) cells are found to have a critical role during the disease progression.
NKT cells may have a protective role at the early stage with simple steatosis through modiﬁcation of insulin resistance, whereas
they act as a progression factor at the advanced stage with ﬁbrosis. Those processes are thought to depend on interaction between
NKT cells and CD1d molecule in the liver.
1.Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most fre-
quent chronic liver disease in the world [1]. NAFLD shows
various degrees of necroinﬂammatory changes and ﬁbrosis
in the liver and has been shown to lead to cirrhosis and
hepatocellular carcinoma (HCC) [2]. As for the progression
of NAFLD from simple fatty liver (FL) to nonalcoholic
steatohepatitis (NASH), the “two-hit theory,” which pro-
poses the accumulation of fat as the ﬁrst hit sensitizes the
liver to a variety of second “hits” leading to hepatic injury,
inﬂammation and ﬁbrosis, has been generally accepted as an
essential mechanism [3], although precise mechanism of the
disease progression is still uncertain.
Because various degrees of inﬂammatory cell inﬁltration
are seen in the livers with NAFLD, especially in NASH,
immunological mechanisms are also thought to be pro-
foundly associated with the pathogenesis and progression of
NAFLD leading to ﬁbrosis or HCC. However, the precise
role of hepatic inﬂammation or contribution of immune
responses in the pathogenesis of NAFLD has not been
clariﬁed yet. Recently, innate immune cells including natural
killer T (NKT) cells have been shown to contribute to the
pathogenesis. In this paper, we summarize and discuss the
role of immune reactions in the pathogenesis of NAFLD,
especially focusing on NKT cells.
2. HepaticNKT Cellsand Their Role in
the Pathogenesis of Liver Diseases
2.1. NKT Cells in the Liver. The liver contains a unique
population of resident mononuclear cells including innate
immune cells such as Kupﬀer cells (KCs) or NKT cells,
possibly because of a defense mechanism against constant
exposure to a variety of toxins and antigens from intestinal
bacteria through portal veins [4]. NKT cells are most
abundant in the liver, and their regulatory roles in hepatic
inﬂammation have been reported [5]. NKT cells are the
uniquesubsetofcells,whichhavebothT-cellreceptor(TCR)
and speciﬁc surface molecules for natural killer cells [6]a n d
are found with up to 30% of the intrahepatic lymphocytes in
mice, and up to 10% of them in humans [7].
2.2. Immunoregulatory Role of NKT Cells. NKT cells are
divided into type 1 and type 2 NKT cells according to
the dependence on the interaction with CD1d, which is
a nonpolymorphic glycolipid antigen-presenting molecule
structurally related to the class I major histocompatibility
complex (MHC). Type 1 NKT cells, which express an
invariant TCR containing Vα14 in mice or Vα24 in human,
recognize glycolipids in conjunction with CD1d, whereas
the repertoire of TCR of Type 2 NKT cells are diverse
although precise character is less well understood [6]. CD1d2 International Journal of Hepatology
is a molecule originally identiﬁed on thymocytes or antigen-
presenting cells [8, 9]. In normal livers, CD1d is mainly
expressed on KCs, but is also expressed on hepatocytes
at a very low level. CD1d molecule is upregulated on
both hepatocytes and bile duct epithelium in liver diseases
including NAFLD [10, 11].
Invariant NKT cells, Type 1 NKT cells, are lipid antigen-
speciﬁc lymphocytes and produce large amounts of T-helper
(Th)1 (e.g., interferon-gamma (IFN-γ), tumor necrosis
factor-alpha (TNF-α)), Th2 (e.g., interleukin (IL)-4, IL-10),
and Th17 (e.g., IL-17, IL-22) cytokines through recognition
of glycolipid antigen presented on CD1d molecules [12].
Thus, invariant NKT cells may act as immune regulators in
various liver diseases. Actually, alterations in the numbers of
hepatic NKT cell have been found in various liver diseases
such as autoimmune hepatitis, primary biliary cirrhosis,
viral hepatitis, or alcoholic and nonalcoholic steatohep-
atitis. In human autoimmune liver diseases, NKT cells
act as proinﬂammatory cells through hepatocyte apoptosis
induced by the release of perforin or granzyme, or by
the increased expression of FasL in addition to cytokine
production such as IFN-γ or TNF-α [13]. The cells also
play anti-inﬂammatory functions through Th2 polarization,
Th17-dependent mechanisms or regulation of other types
of immunoregulatory cells such as regulatory T cells [6, 13,
14]. In murine, a number of studies using concanavalin-A-
(ConA-) induced hepatitis or alpha galactosylceramide (α-
GalCer) induced hepatitis, both of which are murine models
of autoimmune hepatitis, have shown the contribution of
NKT cells in the disease progression [13, 15]. Collectively,
hepatic NKT cells have both proinﬂammatory and anti-
inﬂammatory functions and play an important regulatory
role in the progression of liver diseases.
2.3. The Interaction between CD1d and NKT Cells in Lipid
Metabolism. On the other hand, the liver has a central role
in lipid metabolism with lipolyis, lipogenesis or fat storage.
A recent study showed that the function of hepatic NKT cells
is rapidly activated by lipids in a CD1d-dependent fashion
[16].Kotaset al.recentlydemonstratedthatCD1d deﬁciency
induces hepatic steatosis and glucose intolerance with high-
fat or choline-deﬁcient diet, and glucose intolerance was
mainly induced by decreased hepatic insulin sensitivity
[17]. Furthermore, CD1d deﬁciency also led to aggravation
of metabolic parameters such as glucose homeostasis and
hepatic lipid metabolism [17]. On the other hand, dietary
fatty acids can modulate antigen presentation to hepatic
NKT cells by a CD1d-dependent manner [18]. CD1d thus
can also modulate insulin resistance and play an important
role in lipid metabolism, leading to the formation of hepatic
inﬂammation through antigen presentation to NKT cells.
3.NKT CellsandNAFLD
As described above, NKT cells modulate hepatic inﬂam-
mation through CD1d recognition in conjunction with
glycolipid antigen. Therefore, it is likely and reasonable to
hypothesize that NKT cells contribute to the pathogenesis of
NAFLD especially in the formation of hepatic inﬂammation
and disease progression.
3.1. The Role of NKT Cells in Animal Models. In murine
models, the association between NKT cells and NAFLD
has been widely analyzed. Depletion of NKT cells has been
reported in ob/ob mice, which are leptin deﬁcient and
regarded as a model of obesity-related fatty liver [19, 20]. In
ob/ob mice, hepatic sensitization toward proinﬂammatory
conditions is induced by endotoxin from gut, increased
production of adipokines, or endoplasmic reticulum (ER)
stress, as seen in human NAFLD [19, 21, 22]. Increase
in adipokine production or ER stress activates cytokine
production from hepatic KCs, especially IL-12, leading to
selective depletion of hepatic NKT cells. Recently, Kremer
et al. reported that hepatic NKT cells are decreased in
hepatosteatosis in KCs- and IL-12-dependent manners [23].
They found that hepatic NKT cells are decreased as hep-
atosteatosis progresses that is developed by choline-deﬁcient
diet, but are preserved in IL-12 deﬁcient mice. Moreover,
administration of lipopolysaccharide leads to increase in
hepatic IL-12 expression, and the depletion of KCs reduced
hepatic IL-12expression and restoredNKT cells.In addition,
administration of probiotics has been reported to improve
high-fat diet-induced hepatic steatosis and insulin resistance
by increasing hepatic NKT cells through reduction in the
production of TNF-α and nuclear-factor-(NF)-κB-binding
activity [24].
Adoptive transfer of NKT cells or treatment with gly-
colipid antigens has been shown to result in a reduction
of hepatic steatosis and improvement of glucose intolerance
in ob/ob mice [25, 26]. Moreover, adrenergic activation by
norepinephrineinjectionhasbeenreportedtoinduceexpan-
sion of NKT cell population and improve hepatic steatosis
[20]. In wild-type mice model fed by choline-deﬁcient diet
or high-fat diet, reduction in hepatic NKT cell numbers
accompaniedbyincreasedTh1cytokineproductionhasbeen
demonstrated [27, 28]. Those overall data show that hepatic
NKT cells are involved in the process of hepatic steatosis
through various metabolic factors or cytokines especially
produced by KCs.
On the other hand, the role of hepatic NKT cells has
not been elucidated during the progression of NAFLD,
because neither ob/ob mice nor mice-fed high-fat diet
develop signiﬁcant liver ﬁbrosis. Recent report by Syn et al.
demonstrated that hepatic NKT cells are increased in the
NAFLD liver partly due to hedgehog pathway activation,
leading to promotion of liver ﬁbrosis through activation of
hepaticstellatecells(HSCs)[29].Collectively,murinestudies
showed that NKT cells seem to act as important players
in fat metabolic disorder and have an important role not
only in hepatic steatosis (ﬁrst hit) process but also in disease
progression (second hit) in the pathogenesis of NAFLD.
3.2. The Role of NKT Cells in Humans. In humans, recent
several studies including our report [30] also have provided
important ﬁndings on the contribution of NKT cells to the
pathogenesis of NAFLD. Xu et al. reported that peripheralInternational Journal of Hepatology 3
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Figure 1: Accumulation of NKT cells in the NAFLD liver with high disease activity. (a) Immunohistochemical study using monoclonal
antibodyagainstforCD56showsaccumulationofCD56+ cellsintheliverofNAFLDwiththediseaseprogresses.(FL;fattyliverversusNASH;
nonalcoholic steatohepatitis). (b) The number of CD56+ or CD68+ cells. CD56+ cells are signiﬁcantly increased as the disease progresses.
(c) Flow cytometric analysis of isolated intrahepatic mononuclear cells with NAFLD. Numbers in the quadrant represent the percentage of
positive cells. Right-upper quadrant represents NKT cells (CD3+CD56+ cells). (d) Flow cytometric analysis of Vα24 and intracytoplasmic
cytokines of gated CD3+CD56+ cells among mononuclear cells isolated from livers with NAFLD. Numbers in each histogram represent the
percentage of positive cells. These data have been previously presented in [30].4 International Journal of Hepatology
NKT cells are decreased in NAFLD patients as compared to
healthy controls [31], may suggesting preferential recruit-
ment of peripheral NKT cells to the liver. Our group recently
analyzed the role of hepatic NKT cells in the pathogenesis
of NAFLD using liver biopsy specimens of 54 patients with
NAFLD [30]. First, we performed immunohistochemical
staining for liver biopsy specimens with NAFLD using mon-
oclonal antibodies against CD56 (NK marker) and CD68
(KCs marker). We found that CD56+ cells are increased
in the liver with NAFLD as the disease progresses (Figures
1(a) and 1(b)). Then, we analyzed the surface markers and
intracytoplasmic cytokines of liver-inﬁltrating cells isolated
from liver biopsy specimens by ﬂow cytometry and found
that the number of CD3+CD56+ NKT cells is increased
in NASH as compared with simple FL (Figure 1(c)). Most
of those NKT cells express Vα24, which is the phenotype
of invariant NKT cells and produce both Th1 and Th2
cytokines in advanced NAFLD (Figure 1(d)). Furthermore,
we demonstrated that antigen-presenting cells such as KCs
are more activated and increased the expression of CD1d
as the disease progresses [30]. Based on those data, we
concluded that hepatic NKT cells could contribute to the
disease progression in NAFLD through CD1d recognition.
More recently, Syn et al. also reported the accumulation of
NKTcellstotheliverinprogressiveNASHaccompaniedwith
hedgehog pathway activation [29]. Furthermore, an increase
in intrahepatic NKT cell has been shown in the livers with
moderate-to-severesteatosisbyAdleretal.[32].Ontheother
hand, Kremer et al. reported a diﬀerent ﬁnding, in which
NKT cells are decreased in the liver with NAFLD as steatosis
developed. However, those results are from a small sample
size with relatively mild NAFLD cases (little steatosis 5 cases,
mild steatosis 4 cases, moderate steatosis 3 cases) [23]. Thus,
because NKT cells are increased in the livers with human
NAFLD at least in cases with advanced stages, they could
contribute to the disease progression.
3.3. Comparisons of the Role of NKT Cells in the Pathogenesis
of NAFLD between Animal Models and Humans. The results
from human studies, in which NKT cells contribute to the
progression of NAFLD, seem to be inconsistent with those
from murine models. In murine models, NKT cells are
decreased in the liver with steatosis [19–21, 23, 28]b u t
NKT cells are increased according to the progression of
N A F L Di nh u m a n s[ 29, 30, 32]. One possible reason in the
diﬀerence between human and mice is a distinct proﬁle of
adipokine production. It has been reported that serum leptin
levels are increased in human NASH [33] but not in mice
models of NAFLD, and administration of leptin to murine
leptin deﬁciency models, ob/ob mice, actually increases the
number of NKT cells [19]. Adipokines such as leptin may
thus have a potential role in the regulation of the numbers of
intrahepatic NKT cells. Alternatively, investigation on simple
steatosis has not fully been done in humans as compared
with murine studies, because patients with simple steatosis
are usually healthy leading to lack of the opportunity to
analyze the disease. Moreover, there has been no murine
model for human NASH [34]. Those diﬀerences might make
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Figure 2: A hypothetical contribution of intrahepatic NKT cells in
the progression of NAFLD at the early (a) and the late stage (b).
Interaction between NKT cells and CD1d could play an important
role in the pathogenesis during the entire phase of NAFLD.
the contribution of NKT cells in NAFLD in humans and
murine inconsistent. Further investigation for the diﬀerence
in the role of NKT cells between human and mice need to be
done in the future.
3.4. Summary and Hypothetical Pathogenesis from Exper-
imental Models (Figure 2). In summary, NKT cells seem
to be decreased by activation of KCs through enhanced
production of IL-12 at an early stage of NAFLD, whereas
those are increased by upregulation of CD1d expression
through increased production of adipokines or gut-derived
microbiota at an advanced stage of NAFLD in humans. NKT
cells may have a protective role at an early stage with simple
steatosis by modiﬁcation of insulin resistance (Figure 2(a)),
whereas they act as a progressive factor at an advanced
stage with ﬁbrosis through increased proinﬂammatoryInternational Journal of Hepatology 5
cytokine production, NF-κB activation, or HSCs activation
(Figure 2(b)). These processes are mainly dependent on
interactionofNKTcellswithCD1dmoleculeintheliver.The
change in degree or pattern of intrahepatic CD1d expression
may thus inﬂuence the numbers or functions of NKT cells.
4. Conclusion
NKT cells have a regulatory role in the pathogenesis of lipid-
metabolic disorder including NAFLD through interaction
with CD1d on antigen-presenting cells. Manipulation of
NKT cells might thus have a therapeutic potential.
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